After a follow up of 8.5 years since the start of the trial the recurrence rate in the placebo group was 27%; none of the patients in the immunotherapy group had a recurrence (p = 0.029), suggesting that in early breast cancer MUC1 immunotherapy is beneficial [142]. This evidence concerns the gene MUC1 and breast cancer.